KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Common Equity (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Common Equity data on record, last reported at $391.5 million in Q4 2025.

  • For Q4 2025, Common Equity rose 11806.33% year-over-year to $391.5 million; the TTM value through Dec 2025 reached $391.5 million, up 11806.33%, while the annual FY2025 figure was $391.5 million, 11806.33% up from the prior year.
  • Common Equity reached $391.5 million in Q4 2025 per RIGL's latest filing, up from $117.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $391.5 million in Q4 2025 and bottomed at -$31.8 million in Q3 2023.
  • Average Common Equity over 5 years is $31.0 million, with a median of -$194500.0 recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 664.62% in 2023, then surged 11806.33% in 2025.
  • A 5-year view of Common Equity shows it stood at $30.4 million in 2021, then plummeted by 144.83% to -$13.6 million in 2022, then tumbled by 110.37% to -$28.6 million in 2023, then surged by 111.48% to $3.3 million in 2024, then soared by 11806.33% to $391.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $391.5 million in Q4 2025, $117.6 million in Q3 2025, and $81.9 million in Q2 2025.